International Psoriasis Council

Advancing Knowledge. Improving Care.

Annika Smith Headshot

Annika

Smith

,

MBBS (HONS1), MPHTM, FRACP, FAAD

Consultant Dermatologist
The Skin Hospital, Darlinghurst
Sydney
,
Australia
Councilor Since: June 6, 2025
IPC Councilor
Dr. Annika Smith is a consultant dermatologist with clinical and academic roles across public and private dermatology centres, including St. Vincent’s Hospital, The Skin Hospital Darlinghurst, and the Melanoma Institute Australia. She undertook part of her specialist training at St. John’s Institute of Dermatology in London and is a Fellow of the Australasian College of Dermatologists. Her clinical and research interests span chronic inflammatory skin disease, advanced therapeutics, and multidisciplinary care, with a particular focus on psoriasis. She is actively involved in initiatives addressing the intersection of psoriasis and cardiometabolic disease, contributing to integrated care models and collaborative networks across dermatology, cardiology, and rheumatology. Dr. Smith has authored peer-reviewed publications, co-authored textbook chapters, and is a regular speaker at national and international conferences. She holds academic appointments at both the University of Sydney and the University of New South Wales and mentors emerging clinician-researchers. As an IPC Councilor, she brings a strong commitment to education, research translation, and improving outcomes for people living with psoriasis through global collaboration, multidisciplinary engagement, and evidence-informed practice.
Last Updated:
07/01/2025

Areas of Interest

Psoriasis and Cardiovascular Disease, Systemic Comorbidities, Advanced Therapeutics, Multidisciplinary Models of Care

Languages Spoken

English

Involvement with Other Organization(s)

Dr. Smith is involved in clinician education, multidisciplinary service development, and research translation, informing policy and practice. She also serves as the national representative for the Skin Inflammation & Psoriasis International Network (SPIN).

What's New

First-Line Biologics in Psoriasis: Evidence from the BADBIR Cohort Study

In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.

Read More »

Recent Advances in Psoriasis: A Year in Review

In this Take Ten with IPC video, Dr. Leandro Leite discusses the most recent advances in psoriasis over the last year (March 2025 – March 2026). Topics include new guidelines, research, and recent studies.

WATCH NOW

Monday, April 6, 2026